Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02925650 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease
A Phase 1 study, sponsored by Annovis Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02925650 is a Phase 1 study that has completed, run by Annovis Bio. The registered enrollment target is 18 participants.
The verdict
NCT02925650, a Phase 1 study, has completed, sponsored by Annovis Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study evaluates the safety and pharmacological effects of 3 different doses of Posiphen® when compared to a placebo, in adult male and female patients with early Alzheimer's disease (AD).
Interventions
- DRUG Placebo
- DRUG Posiphen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2017-03-02 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02925650
The ClinicalTrials.gov registry entry for NCT02925650 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Annovis Bio, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02925650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02925650 about?
NCT02925650 is a clinical study titled "Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease". This study evaluates the safety and pharmacological effects of 3 different doses of Posiphen® when compared to a placebo, in adult male and female patients with early Alzheimer's disease (AD).
What is the current status of trial NCT02925650?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2017-03-02. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT02925650?
The interventions under investigation include: Placebo (DRUG), Posiphen (DRUG).
Who is sponsoring clinical trial NCT02925650?
This trial is sponsored by Annovis Bio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.